<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1698">
  <stage>Registered</stage>
  <submitdate>19/09/2007</submitdate>
  <approvaldate>19/09/2007</approvaldate>
  <nctid>NCT00532688</nctid>
  <trial_identification>
    <studytitle>N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure</studytitle>
    <scientifictitle>Randomised Control Pilot Trial of n-Acetylcysteine in the Treatment of Chronic Heart Failure With Coexistent Chronic Renal Failure.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>132/07</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure, Congestive</healthcondition>
    <healthcondition>Kidney Failure, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - N-acetylcysteine

Experimental: 1 - 5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.

Placebo Comparator: 2 - 28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.


Treatment: drugs: N-acetylcysteine
28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Vascular function via non invasive ultrasound measured flow mediated dilatation</outcome>
      <timepoint>baseline, 4 weeks and 9 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Estimated glomerular filtration rate calculated with Cockroft Gault equation.</outcome>
      <timepoint>baseline, 4 weeks, 9 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptoms of heart failure</outcome>
      <timepoint>baseline, 4 weeks, 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death</outcome>
      <timepoint>baseline, 4 weeks, 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum BNP (brain natriuretic peptide)</outcome>
      <timepoint>baseline, 4 weeks, 9 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18 to 75 years inclusive;

          -  Patients with chronic heart failure NYHA II, III and IV and LVEF&lt;40%. Stable
             medications for 1 month. Not admitted to hospital in the past month.

          -  Chronic renal failure with GFR (as estimated by the Cockroft Gault equation) of &gt;30
             ml/min and &lt;50 ml/min not on any form of dialysis.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Age &lt;18 and &gt;75 years;

          -  Myocardial infarction in the preceding six months;

          -  Acute decompensation of renal function or heart failure in the last 30 days;

          -  Allergy to n-acetylcysteine or glyceryl trinitrate;

          -  Contraindications to the use of glyceryl trinitrate as per the product information
             lodged with the PBS (Australia);

          -  On treatment with allopurinol, vitamin C or vitamin E or other antioxidant therapy at
             time of randomisation (statins are acceptable);

          -  Acute decompensation of another organ system in the last 30 days;

          -  Current pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2008</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The Alfred</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Treatment with n-acetylcysteine in patients with heart failure and chronic renal failure
      leads to improvements in vascular function and in renal function.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00532688</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Kaye, PhD FRACP</name>
      <address>Alfred Heart Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>David Kaye, PhD FRACP</name>
      <address />
      <phone>610390762000</phone>
      <fax />
      <email>david.kaye@baker.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>